LNP 509

Known as: dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrrol-2-yl)amine, lnp-509 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2017
0120012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
This article describes the preclinical pharmacology and pharmacokinetics (PK) of hexadecyl-treprostinil (C16TR), a prodrug of… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2015
2015
The present study aimed at establishing feasibility of delivering short interfering RNA (siRNA) to target the coagulation cascade… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2006
2006
This work aimed to study the respective effects of central alpha2-adrenergic receptors (alpha2-ARS) and I1 imidazoline receptors… (More)
Is this relevant?
2002
2002
BACKGROUND Both alpha(2)-adrenergic and non--alpha(2)-adrenergic mechanisms seem to be involved in the hypotensive effect of… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2002
2002
Background—Both 2-adrenergic and non– 2-adrenergic mechanisms seem to be involved in the hypotensive effect of imidazoline-like… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2001
2001
To find new compounds selective for purported I1 imidazoline receptors (I1Rs) over I2 imidazoline binding sites (I2BS) and alpha2… (More)
Is this relevant?